Skip to main content
Log in

Agranulocytosis due to an α-glucosidase inhibitor, voglibose

  • Letter to Editor
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care. 1998;21:256–60.

    Article  CAS  PubMed  Google Scholar 

  2. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373:1607–14.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hidekatsu Yanai.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoshikawa, R., Hishinuma, R., Kaneko, H. et al. Agranulocytosis due to an α-glucosidase inhibitor, voglibose. Int J Diabetes Dev Ctries 35, 384–385 (2015). https://doi.org/10.1007/s13410-014-0242-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-014-0242-7

Keywords

Navigation